ArticleClinical kidney journal2022
Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort.
Article in Clinical kidney journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Trial
- Health Care Resource Utilization and Associated Costs Across Proteinuria and Declining Kidney Function in Patients With IgA Nephropathy: A Retrospective Study in Three European Countries.Kidney medicine · 2026Article
- Impact of Increased SGLT2 Inhibitor Uptake in CKD Management in Denmark: Modeling National Patient Benefits and Cost Savings.Kidney medicine · 2026Article
- Article
- International Environmental Impact of CKD Care.Kidney international reports · 2026Article
- Patient Referral and Education Program Prior to Renal Replacement Therapy (PREP-RRT): A Pilot Study.Journal of general internal medicine · 2026Article
- Article
- The role of social networks in supporting self-management in CKD: a narrative synthesis.BMC nephrology · 2025Review
- The evolution of consultation practices with general practitioners and nephrologists for patients with chronic kidney disease before and after the COVID-19 pandemic in France.Journal of nephrology · 2025Article
- The Cost-Effectiveness of Initiating Patients on Home Dialysis Compared with In-Centre Haemodialysis.Applied health economics and health policy · 2025Article
- Learning from the implementation phase of the new French capitation payment model for chronic kidney disease care: a qualitative study.Journal of nephrology · 2025Article
- Future Designs of Clinical Trials in Nephrology: Integrating Methodological Innovation and Computational Power.Sensors (Basel, Switzerland) · 2025Review
- Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Development, Rasch analysis and validation of the kidney symptom burden questionnaire (KSB-Q).Clinical kidney journal · 2025Article
- Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study.BMC primary care · 2025Observational
- Healthcare costs in relation to kidney function among older people: the SCOPE study.European geriatric medicine · 2025Article
- Relationship between kidney function and healthy life expectancy: A historical cohort study.BMC nephrology · 2025Article
- A Primary Care Guide to the Screening and Pharmacologic Management of Chronic Kidney Disease in People Living With Type 2 Diabetes.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Sox17 mediates venous adaptive remodeling after arteriovenous fistula creation.JVS-vascular science · 2025Article
- Using Chronic Kidney Disease as a Model Framework to Estimate Healthcare-Related Environmental Impact.Advances in therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) is widely reported to decrease quality of life, increase morbidity and mortality and cause increased healthcare resource utilisation (HCRU) as the disease progresses. However, there is a relative paucity of accurate and recent estimates of HCRU in this patient population. Our aim was to address this evidence gap by reporting HCRU and related costs in patients with CKD from the UK primary and secondary care settings. Methods: HCRU and cost estimates of CKD were derived for UK patients included in the DISCOVER CKD cohort study using clinical records from the Clinical Practice Research Datalink linked to external databases. Patients with a history of transplant or undergoing dialysis were not included. HCRU and costs were stratified by CKD severity using the urinary albumin:creatinine ratio (UACR) and estimated glomerular filtration rate. Results: Hospitalisation rates more than tripled between low (A1) and high (A3) UACR categories and the mean annual per-patient costs ranged from £4966 (A1) to £9196 (A3) and from £4997 (G2) to £7595 (G5), demonstrating that a large healthcare burden can be attributed to a relatively small number of patients with later stage CKD, including those with kidney failure and/or albuminuria. Conclusions: HCRU and costs associated with CKD impose a substantial burden on the healthcare system, particularly in the more advanced stages of CKD. New interventions that can delay the progression of CKD to kidney failure may not only prolong the patient's life, but would also provide significant resource and cost savings to healthcare providers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.